Literature DB >> 9369349

Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.

V De Gennaro Colonna1, G Rossoni, M Bernareggi, E E Müller, F Berti.   

Abstract

The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum. Heart preparations from anti-GHRH serum-treated rats, undergoing low-flow ischemia and reperfusion, showed: (1) a progressive increase of left ventricular end-diastolic pressure during the ischemic period and a poor recovery of contractility at reperfusion with a consistent decrease of the left ventricular-developed pressure; (2) a decreased rate of formation of 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha), a stable metabolite of prostacyclin, in perfusates from preischemic and reperfusion periods; (3) an increased vasopressor activity of angiotensin II. Hexarelin (80 microg/kg, bid, s.c.), administered for 15 days to anti-GHRH serum-treated rats, restored to normal the impaired somatotropic function and counteracted the ischemic damage, improving postischemic left ventricular developed pressure to values higher than those of controls. Furthermore, both the generation of 6-keto-PGF1alpha and the vasopressor activity of angiotensin II reverted to those of control preparations. Administration of hexarelin to control rats induced a considerable improvement of postischemic ventricular function of the perfused hearts which was similar to that present in preparations from anti-GHRH serum-treated rats given hexarelin. This protective activity was divorced from any further stimulation of somatotropic function. Collectively, these data indicate that, in GH-deficient rats, hexarelin is capable of restoring somatotropic function and has a beneficial effect in myocardial ischemia and reperfusion damage. In addition, the increased responsiveness of the coronary vasculature to angiotensin II and the decreased generation of prostacyclin in hearts from GH-deficient rats would indicate that for prevention of injury and dysfunction of the vascular endothelium a normal somatotropic function is mandatory.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369349     DOI: 10.1016/s0014-2999(97)01178-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  Current topics in GH secretagogue research--introduction.

Authors:  Barry B Bercu; Richard F Walker
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.633

Review 2.  Ghrelin and GHS on cardiovascular applications/functions.

Authors:  J Isgaard; I Johansson
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

3.  Hexarelin, but not growth hormone, protects heart from damage induced in vitro by calcium deprivation replenishment.

Authors:  A Torsello; G Rossoni; V Locatelli; V De Gennaro Colonna; M Bernareggi; M Francolini; E E Müller; F Berti
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 4.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

5.  Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.

Authors:  L C Pan; P A Carpino; B A Lefker; J A Ragan; S M Toler; J C Pettersen; D O Nettleton; O Ng; C M Pirie; K Chidsey-Frink; B Lu; D F Nickerson; D A Tess; M A Mullins; D B MacLean; P A DaSilva-Jardine; D D Thompson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 6.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

7.  Hexarelin: a multi-receptor peptide.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 8.  Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

9.  Ghrelin and cardiovascular diseases.

Authors:  Gaigai Zhang; Xinhua Yin; Yongfen Qi; Lakshmana Pendyala; Jack Chen; Dongming Hou; Chaoshu Tang
Journal:  Curr Cardiol Rev       Date:  2010-02

10.  Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor.

Authors:  Sabata Pierno; Annamaria De Luca; Jean-François Desaphy; Bodvael Fraysse; Antonella Liantonio; Maria Paola Didonna; Marcello Lograno; Daniela Cocchi; Roy G Smith; Diana Conte Camerino
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.